Please login to the form below

Not currently logged in
Email:
Password:

Astellas signs antibody agreement

Japan-based pharmaceutical firm Astellas is to enter a license agreement with biotechnology firm Evec for its antibody programme to fight infectious diseases

Japan-based pharmaceutical firm Astellas is to enter a license agreement with biotechnology firm Evec for its antibody programme to fight infectious diseases.

The deal will see Astellas gain worldwide rights to develop, manufacture and commercialise the related antibodies, with the programme still in a pre-clinical phase.

Evec will receive an upfront payment of 0.6bn yen, with potential milestone payments based on development and sales success of up to 13bn yen.

The company specialises in the development of a number of human monoclonal antibodies across several therapeutic areas, including cancer, inflammatory diseases and infectious diseases.

6th September 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics